Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.57 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7329940 | 0.84 | F2RL1 (0.85) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL30792366 | 0.82 | FFAR1 (0.81) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL274471 | 0.82 | FFAR1 (0.81) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL2468017 | 0.82 | SMN1; SMN2 (0.72) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL1334 | 0.82 | SMN1; SMN2 (0.72) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL9404116 | 0.81 | F2RL1 (1.00) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL1445627 | 0.81 | F2RL1 (0.73) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL2487562 | 0.81 | F2RL1 (0.68) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL2338537 | 0.81 | AKR1B1 (0.47) | F2RL1ALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL925662 | 0.81 | F2RL1 (0.68) | F2RL1FFAR1ALDH1A1POLBNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664272-B2 | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-03-04 | — | — | US | disclosed |
| US-8273787-B2 | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions | ONCONOVA THERAPEUTICS, INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8106033-B2 | (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid; antiproliferative; anticarcinogenic agent : solid tumors, leukemia; \"cytoproliferative\" diseases: atherosclerosis, fibrosis, Paget's disease; synergistic effect with other active ingredients | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | ONCONOVA THERAPEUTICS, INC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20080161252-A1 | Composition and Methods For the Treatment of Proliferative Diseases | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033475-A2 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | ONCONOVA THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008027049-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1487428-A4 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1487428-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003072062-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-1999040882-A2 | STEREOSELECTIVE Tc-99m LIGANDS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-08-19 | — | — | WO | disclosed |
| US-4225617-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-09-30 | — | — | US | disclosed |
| US-4209524-A | CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4209523-A | TREATMENT OF THE CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4183951-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-01-15 | — | — | US | disclosed |
| US-4152458-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1979-05-01 | — | — | US | disclosed |
| US-4151300-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC | LABORATOIRE L. LAFON (FR) | 1979-04-24 | — | — | US | disclosed |
| US-4122186-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161252-A1 | Composition and Methods For the Treatment of Proliferative Diseases | CCNH, POLH, CCNO | F2RL1 4833/4885FFAR1 3904/4885ALDH1A1 1363/4885 |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | DNMT3A, TET2, MCL1 | F2RL1 4019/4885FFAR1 3518/4885ALDH1A1 1255/4885 |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | CCNY, CCND2, CCNB1 | F2RL1 4164/4885FFAR1 2016/4885ALDH1A1 2155/4885 |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | CD40, TNFRSF9, NGFR | F2RL1 324/4885FFAR1 1011/4885ALDH1A1 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.